XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
ORLADEYO:
U.S.$72,817 $58,702 $133,666 $102,637 
Outside of U.S.8,192 6,521 15,757 12,290 
Total ORLADEYO81,009 65,223 149,423 114,927 
Other revenues1,482 309 1,846 528 
Total revenues$82,491 $65,532 $151,269 $115,455 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues and royalties. Other revenues primarily relate to the Company’s galidesivir development contracts with BARDA/HHS and NIAID/HHS and product sales and royalties for peramivir injection (RAPIVAB/RAPIACTA/PERAMIFLU).